The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide-Reference-Cited by-同舟云学术

The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide

Published:2024-05-06 Issue:9 Volume:65 Page:1270-1280
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

von dem Borne Peter A.¹,Kemps-Mols Berit M.²,de Wreede Liesbeth C.³,van Beek Adriaan A.²,Snijders Tjeerd J.F.⁴,van Lammeren Daniëlle⁵,Tijmensen Janneke⁶,Sijs-Szabó Aniko¹,Oudshoorn Mirjam A.¹,Halkes Constantijn J.M¹,van Balen Peter¹,Marijt W.A. Erik¹,Tjon Jennifer M.L.¹,Vermaat Joost S.P¹^ORCID,Veelken Hendrik¹

Affiliation:

1. Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands

2. Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands

3. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands

4. Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands

5. Department of Hematology, Haga ziekenhuis, Den Haag, The Netherlands

6. Department of Hematology, Reinier de Graaf Gasthuis, Delft, the Netherlands

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2344060

Reference44 articles.

1. HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

2. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation

3. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression

4. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding

5. High Fever Occurring 4 to 5 Days Post-Transplant of Haploidentical Bone Marrow or Peripheral Blood Stem Cells after Reduced-Intensity Conditioning Associated with the Use of Post-Transplant Cyclophosphamide as Prophylaxis for Graft-versus-Host Disease